Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio Growth (3y) (2016 - 2026)
Alnylam Pharmaceuticals (ALNY) Interest Coverage Ratio Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -11.54% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 82.53% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 43.08% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 28.57% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -26.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -24.77% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 33.30% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 81.16% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -24.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.30% |
| Mar 31, 2026 | 40.09% |
| Dec 31, 2025 | 495.24% |
| Sep 30, 2025 | 49.18% |
| Jun 30, 2025 | 55.27% |
| Mar 31, 2025 | 27.56% |
| Dec 31, 2024 | -17.30% |
| Sep 30, 2024 | 20.85% |
| Jun 30, 2024 | 32.65% |
| Mar 31, 2024 | 40.08% |
| Dec 31, 2023 | -46.44% |
| Sep 30, 2023 | 42.33% |
| Jun 30, 2023 | -1.59% |
| Mar 31, 2022 | -64.92% |
| Dec 31, 2021 | -174.25% |
| Sep 30, 2021 | 77.86% |
| Jun 30, 2021 | 71.46% |
| Dec 31, 2020 | 62.62% |
| Sep 30, 2020 | 68.53% |
| Jun 30, 2020 | 71.06% |